�MicroIslet Inc. (OTCBB: MIIS), a biotech company in use in the development and commercialization of cell therapies for diabetes, is pleased to reputation on the Company's presentment at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet's Senior Director and Vice President of R&D, severally, discussed the Company's developmental advances at the globular transplantation meeting.
MicroIslet's presentation outlined the extensive amount of presymptomatic data the Company has complied o'er the last-place few geezerhood. In compact, MicroIslet has tested MicroIslet-P�, the Company's lead ware candidate, in hundreds of rodents and has lately completed a trial with nineteen nonhuman primates, some of which received up to trine separate transplant procedures. The numerous transplantations of MicroIslet-P�resulted in no observed base hit issues, while producing significant improvements in blood glucose levels.
"MicroIslet presented information in Sydney that demonstrated that our lead production candidate, MicroIslet-P, was a safe and effective treatment in rodents and order Primates that had been rendered diabetic," said Dr. Stuiver. "Over the last geezerhood, our preclinical testing of MicroIslet-P has been extensive and thorough. We are proud of our results and late developmental progression, and remain on butt for human dosing in the fourth quarter of 2008."
Dr. Amaresh Basu added, "The response and feedback we received from the conference participants in Sydney was very encouraging. We were quite pleased to share our advances with such a respected group of our comrade researchers and industry peers. With our preclinical programs now nearly complete, MicroIslet-P is self-collected to act into human clinical testing."
About MicroIslet, Inc.
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of cell therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University for isolation, culturing, storage, and microencapsulation of insulin-producing islet cells from porcine sources. The Company believes that these technologies, and other proprietary methods developed in-house, are substantial advances in the field of cellular therapeutics. MicroIslet is planning human clinical trials in the U.S., and exploring possible trials abroad. MicroIslet's ultimate goal is to offer jail cell transplantation therapies for diabetic patients general.
The Company's lead product, MicroIslet-PTM, consists of microencapsulated porcine islets for implantation into the abdominal cavity using a minimally invasive procedure. Microencapsulation involves circumferent islet cells with formulations of a highly biocompatible, ultra-pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coat allows insulin, glucose, oxygen and other nutrients to diffuse freely, while block antibodies and reducing the patient's immune response to the ingrained islet cells. It is hoped that MicroIslet-PTM will provide physiological and self-acting blood glucose control, thus reducing the need for insulin injections or infusions and constant blood glucose monitoring. The long term complications associated with type 1 diabetes, such as peripheral neuropathies, heart and kidney disease, and skin disorders, english hawthorn be mitigated by the tighter blood glucose control that would result from such a product.
Additional information close to MicroIslet keister be constitute at hTTP://www.microislet.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press handout are advanced statements within the signification of the "Safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These innovative statements ar subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet's on the job capital deficit, which includes a substantial amount of indebtedness which is full-blown and imputable on demand; MicroIslet's need to raise substantial extra funds in order to fund its development design and continue as a going worry; the risks and uncertainties inherent in medical discourse discovery; development and commercialization; the risks and uncertainties associated with MicroIslet's early stage xenotransplant technologies; the risks and uncertainties of governmental approvals and regulation, including extraneous government approvals for clinical trials external the United States; dependency on a sole source supplier of animal parts and a sole source manufacturer of encapsulated islets for presymptomatic and clinical studies; the risks that MicroIslet's competitors will develop or market technologies or products that are more than effective or commercially attractive than MicroIslet's products; and other risks detailed from time to time in MicroIslet's near recent filings with the Securities and Exchange Commission. These advanced statements talk only as of the date hereof. MicroIslet disclaims any spirit or indebtedness to update these modern statements.
More info
